文献速递骨肌技术与安全CT

化疗后骨转移的定量增强CT衰减评估

Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.
PubMed 文献 · Skeletal Radiol · 2017-06-30

研究纳入86例癌症患者,在化疗前及化疗开始后14±2个月行增强CT,测量骨转移灶的平均和最大CT衰减值(HU)。化疗后所有患者转移灶平均和最大衰减值均显著增加;在平均衰减值下降的亚组中,更多患者临床状态恶化。

要点

  • 化疗后骨转移灶平均和最大CT衰减值在14±2个月时显著增加。
  • 按病变类型、临床状态、癌症类型和放疗分层后,衰减值增加仍有统计学意义。
  • 平均衰减值下降的亚组中,79%患者临床状态恶化。

核心结论

  • 定量CT衰减测量显示,化疗开始后超过12个月骨转移灶衰减值有统计学显著增加。

研究设计与样本

  • 经IRB批准并符合HIPAA的队列研究,纳入86例连续癌症患者,在化疗前及化疗开始后14±2(12-25)个月行增强CT,由两名阅片者测量HU,采用配对t检验和Fisher精确检验,并计算组内相关系数(ICC)。

关键影像表现/征象

  • 病变类型分布为溶骨性30/86(35%)、成骨性43/86(50%)、混合溶骨-成骨性13/86(15%)。
  • 化疗后所有患者转移灶平均和最大CT衰减值均显著增加。

诊断标准与关键数值

  • 平均衰减值的组内相关系数(ICC)几乎完美,最大衰减值的ICC为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Osseous metastases often undergo an osteoblastic healing response following chemotherapy. The purpose of our study was to demonstrate the quantitative CT changes in attenuation of osseous metastases before and after chemotherapy.

MATERIALS AND METHODS: Our study was IRB approved and HIPAA compliant. Our cohort consisted of 86 consecutive cancer patients with contrast-enhanced CTs before and 14 ± 2 (12-25) months after initiation of chemotherapy (60 ± 11 years, 36 males, 50 females). The average and maximum metastasis attenuations were measured in Hounsfield units (HU) by two readers. Treatment effects were assessed using paired t-tests and Fisher exact tests. Intraclass correlation coefficients (ICCs) were calculated. Patient records were reviewed to determine the patient's clinical status (worse, unchanged, or improved) at the time of follow-up CT.

RESULTS: The distribution of lesion types was as follows: lytic (30/86, 35%), blastic (43/86, 50%), and mixed lytic-blastic (13/86, 15%). There was a significant increase in average and maximum CT attenuation of metastases following chemotherapy for all patients, which remained statistically significant when stratified by lesion type, clinical status (worsening or improving/stable), cancer type (breast, lung), and radiation therapy (P < 0.05). In a subgroup of patients whose osseous metastases decreased in average attenuation (14/86, 16%), more patients had a worse clinical status (11/14, 79%) (P = 0.02). ICC was almost perfect for average attenuation and substantial for maximum attenuation.

CONCLUSION: Quantitative assessment of osseous metastatic disease using CT attenuation measurements demonstrated a statistically significant increase in attenuation more than 12 months after initiation of chemotherapy.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Chang CY, Simeone FJ, Torriani M, et al. Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy. Skeletal Radiol. 2017. PMID: 28667362. doi:10.1007/s00256-017-2706-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。